Descriptor English: | Anistreplase | ||||||
Descriptor Spanish: |
Anistreplasa
| ||||||
Descriptor Portuguese: | Anistreplase | ||||||
Descriptor French: | Anistreplase | ||||||
Entry term(s): |
APSAC Anisoylated Plasminogen-Streptokinase Activator Complex BRL 26921 BRL-26921 BRL26921 Eminase Iminase |
||||||
Tree number(s): |
D08.811.277.656.300.760.635.075 D08.811.277.656.300.775.075 D08.811.277.656.959.350.635.075 D12.776.124.125.662.537.075 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D016255 | ||||||
Scope note: | An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents. |
||||||
Allowable Qualifiers: |
AD administration & dosage AE adverse effects AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis DE drug effects DF deficiency EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UL ultrastructure UR urine |
||||||
Pharm Action: |
Fibrinolytic Agents |
||||||
Registry Number: | 81669-57-0 | ||||||
CAS Type 1 Name: | Anistreplase | ||||||
Previous Indexing: |
Fibrinolytic Agents (1966-1990) Plasminogen (1966-1990) Streptokinase (1966-1990) |
||||||
Public MeSH Note: | 91 |
||||||
History Note: | 91 |
||||||
DeCS ID: | 28860 | ||||||
Unique ID: | D016255 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1991/01/01 | ||||||
Date of Entry: | 1990/05/07 | ||||||
Revision Date: | 2016/07/01 |
-
-
CHEMICALS AND DRUGS
Enzymes and Coenzymes [D08]Enzymes and Coenzymes -
CHEMICALS AND DRUGS
Enzymes and Coenzymes [D08]Enzymes and Coenzymes -
CHEMICALS AND DRUGS
Enzymes and Coenzymes [D08]Enzymes and Coenzymes -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Anistreplase
- Preferred
Iminase
- Narrower
BRL-26921
- Narrower
Eminase
- Narrower
Concept UI |
M0024829 |
Scope note | An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents. |
Preferred term | Anistreplase |
Entry term(s) |
APSAC Anisoylated Plasminogen-Streptokinase Activator Complex |
Concept UI |
M0433989 |
Preferred term | Iminase |
Concept UI |
M0333009 |
Preferred term | BRL-26921 |
Entry term(s) |
BRL 26921 BRL26921 |
Concept UI |
M0024830 |
Preferred term | Eminase |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey